RESUMO
OBJECTIVES: Squamous cell carcinoma (SCC) is the most common tumour in the nasal planum of cats. Surgery has traditionally been the treatment of choice but might not be feasible in locally advanced scenarios. Electrochemotherapy (ECT) has shown good control in superficial tumours, but there is a lack of robust information about efficacy in locally advanced cases. The aim of this study was to assess the safety and efficacy of ECT in the treatment of locally advanced stage nasal planum SCC in cats. METHODS: The clinical database of a veterinary referral hospital was searched retrospectively for cats diagnosed with a locally advanced nasal planum SCC (T3N0M0 or T4N0M0) that had received ECT. Local response, adverse events and outcome were documented. The data were evaluated by inferential statistics and correlations between response, recurrence, feline immunodeficiency virus/feline leukaemia virus status, number of treatments, voltage and severity of adverse events, with Kaplan-Meier curves and log-rank tests. Statistical significance was set at P <0.05. RESULTS: In total, 21 cats were enrolled over a 4-year period. Nineteen cats achieved a complete response (CR) and two cats a partial response (PR) for an overall response rate of 100%. Cats achieving a CR had a median disease-free interval of 182 days (range 128-327) and those with a PR had a median progression-free survival of 156.5 days (range 122-191). The median time to progression was not reached. The overall survival was 453 days for a median follow-up of 341 days (range 191-989). Of the cats, 62% had grade 3 or 4 toxicities, but no deaths due to the treatment were documented. Only voltage was correlated with longer survival (P = 0.001). CONCLUSIONS AND RELEVANCE: ECT appears to be an effective treatment for feline nasal planum SCC and could be considered a first-line therapy for locally advanced cases. Toxicities reported can be severe in the short term and these could be secondary to more invasive lesions and equipment used.
Assuntos
Carcinoma de Células Escamosas , Doenças do Gato , Eletroquimioterapia , Neoplasias Nasais , Animais , Gatos , Doenças do Gato/tratamento farmacológico , Eletroquimioterapia/veterinária , Carcinoma de Células Escamosas/veterinária , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/mortalidade , Masculino , Estudos Retrospectivos , Feminino , Neoplasias Nasais/veterinária , Neoplasias Nasais/tratamento farmacológico , Resultado do TratamentoRESUMO
Electrochemotherapy (ECT) with intravenous (IV) and/or intratumoral (IT) bleomycin has shown considerable efficacy in the treatment of non-resectable feline cutaneous squamous cell carcinoma (cSCC), boasting response rates of up to 95%, but other chemotherapy protocols have not yet been investigated. The objective of this prospective multicentre study was to compare the overall response rate (ORR) and progression-free interval (PFI) between cats with cSCC treated with ECT using IT and IV carboplatin (IV + IT), IV carboplatin (IV) or IV bleomycin (IV). A total of 44 cats with unresectable cSCC across three centres were enrolled and treated with ECT using carboplatin IV + IT (n = 10), carboplatin IV (n = 11) or bleomycin IV (n = 23). Treatment response according to RECIST criteria was recorded at 2 and 4 weeks post-treatment, and patients were followed until disease progression and/or death. All three groups were comparable regarding age, sex, weight, and lesion size. Adverse events were generally mild, localised and similar between groups. ORRs were 90.0% (carboplatin IV + IT), 90.9% (carboplatin IV) and 95.6% (bleomycin IV) and were not significantly different (p = 0.79). Median PFI was not reached for carboplatin IV + IT or carboplatin IV and was 566 days for bleomycin IV, with no significant difference between the three groups (p = 0.81). This study suggests that ECT using IV or IV + IT carboplatin is a reasonable alternative therapeutic option for managing cSCC, and further studies are warranted to compare outcomes between treatment protocols.
Assuntos
Antineoplásicos , Bleomicina , Carboplatina , Carcinoma de Células Escamosas , Doenças do Gato , Eletroquimioterapia , Neoplasias Cutâneas , Animais , Gatos , Eletroquimioterapia/veterinária , Eletroquimioterapia/métodos , Bleomicina/uso terapêutico , Bleomicina/administração & dosagem , Neoplasias Cutâneas/veterinária , Neoplasias Cutâneas/tratamento farmacológico , Doenças do Gato/tratamento farmacológico , Carboplatina/uso terapêutico , Carboplatina/administração & dosagem , Feminino , Masculino , Carcinoma de Células Escamosas/veterinária , Carcinoma de Células Escamosas/tratamento farmacológico , Antineoplásicos/uso terapêutico , Antineoplásicos/administração & dosagem , Estudos Prospectivos , Resultado do TratamentoRESUMO
Electrochemotherapy (ECT) is a treatment modality that combines the electroporation of cell membranes with chemotherapy to facilitate the transport of non-permeant molecules into cells. Several canine and feline studies have shown promising results, suggesting that ECT can be a valid adjuvant or alternative treatment option for some tumours. The objective of this paper is to provide a bibliographic review of the principles and applications of ECT in veterinary medicine and to compare to its use in human medicine.
Assuntos
Doenças do Gato , Doenças do Cão , Eletroquimioterapia , Neoplasias , Gatos , Cães , Eletroquimioterapia/veterinária , Eletroquimioterapia/métodos , Animais , Doenças do Cão/tratamento farmacológico , Doenças do Gato/tratamento farmacológico , Neoplasias/veterinária , Neoplasias/tratamento farmacológico , Antineoplásicos/uso terapêuticoRESUMO
Background: During electrochemotherapy (ECT), a chemotherapeutic drug is injected into the tumor and then an electroporation is provided. In horses, ear manipulation may be very painful, and combining a loco-regional technique with sedation might be a good option to avoid anesthesia-related risks. A two-injection-point block of the internal and external pinna and acoustic meatus was described in horse cadavers, and it permitted complete stain of all three branches of the great auricular nerve (GAN), internal auricular nerve branch (IAB), lateral auricular branch (LAB), and caudal auricular nerve (CAN), suggesting a lower risk of intra-parotid injection during the IAB and LAB block. Case Description: An 8-year-old Italian jumping gelding presented for ECT to treat a fibroblastic sarcoid in the left medial pinna. After intravenous sedation with acepromazine, romifidine, and butorphanol, a two-injection-point block was provided as previously described. The block of the GAN was blind, whereas an electrical nerve locator was used for the IAB, LAB, and CAN. A total of 12 ml of 0.5% ropivacaine was injected. The ECT was safely performed without any difficulties. The horse well tolerated the procedure and completely recovered 75 minutes after sedation. No complications were detected. Conclusion: The described approach seems feasible and suitable for the blockade of the sensory innervation of the equine ear in the case of ECT.
Assuntos
Doenças dos Cavalos , Cavalos , Animais , Doenças dos Cavalos/terapia , Masculino , Eletroquimioterapia/veterinária , Dor/veterinária , Dor/etiologia , Ropivacaina/administração & dosagem , Anestésicos Locais/administração & dosagem , Bloqueio Nervoso/veterináriaRESUMO
The combined treatment of electrochemotherapy (ECT) and interleukin-12 (IL-12) gene electrotransfer (GET) has already been used in clinical studies in dogs to treat various histological types of spontaneous tumors. The results of these studies show that the treatment is safe and effective. However, in these clinical studies, the routes of administration of IL-12 GET were either intratumoral (i.t.) or peritumoral (peri.t.). Therefore, the objective of this clinical trial was to compare the two IL-12 GET routes of administration in combination with ECT and their contribution to the enhanced ECT response. Seventy-seven dogs with spontaneous mast cell tumors (MCTs) were divided into three groups: one treated with a combination of ECT + GET peri. t. (29 dogs), the second with the combination of ECT + GET i.t. (30 dogs), and the third with ECT alone (18 dogs). In addition, immunohistochemical studies of tumor samples before treatment and flow cytometry of peripheral blood mononuclear cells (PBMCs) before and after treatment were performed to determine any immunological aspects of the treatment. The results showed that local tumor control was significantly better in the ECT + GET i.t. group (p < 0.050) than in the ECT + GET peri.t. or ECT groups. In addition, disease-free interval (DFI) and progression-free survival (PFS) were significantly longer in the ECT + GET i.t. group than in the other two groups (p < 0.050). The data on local tumor response, DFI, and PFS were consistent with immunological tests, as we detected an increased percentage of antitumor immune cells in the blood after treatment in the ECT + GET i.t. group, which also indicated the induction of a systemic immune response. In addition, we did not observe any unwanted severe or long-lasting side effects. Finally, due to the more pronounced local response after ECT + GET i.t., we suggest that treatment response assessment should be performed at least two months after treatment, which meets the iRECIST criteria.
Assuntos
Doenças do Cão , Eletroquimioterapia , Transtornos Mieloproliferativos , Neoplasias , Animais , Cães , Doenças do Cão/tratamento farmacológico , Eletroquimioterapia/métodos , Eletroquimioterapia/veterinária , Interleucina-12/genética , Leucócitos Mononucleares , Transtornos Mieloproliferativos/tratamento farmacológico , Neoplasias/tratamento farmacológicoRESUMO
Squamous cell carcinoma (SCC) is an important malignancy in dogs, due to its incidence and clinical presentation, which can be of locally aggressive single or multiple lesions with a metastatic potential. The objective of this investigation was to evaluate SCC response to treatment, anatomopathological and immunohistochemical characteristics, disease-free interval and overall survival time. 54 dogs with histopathologically diagnosed SCC were included in this study. Their mean age was 9.16 years with a range of 1-14 years. Of the 54 animals in the study, 34 (65.4%) had white skin and white fur coats. There was a significant correlation between fur coat colour and the development of tumours in areas of sun exposure (p = .001). Animals with tumours in areas of the body exposed to the sun had longer overall survival time than animals with tumours in areas not associated with sun exposure (p = .001). Surgery combined with electrochemotherapy (ECT) yielded a survival rate 32% higher than using a surgical approach alone (HR = 0.32, p = .038, IC = 0.11-0.94). ECT, with or without surgery, had an objective response rate of 90.9%. Local lymph node and/or distant site metastasis at diagnosis, or at some point during follow-up, occurred in 34.6% (18/52) of animals. Animals with tumours in sun exposed locations had more aggressive histopathological characteristics but had longer overall survival time. This is probably due to individualised therapeutic treatment with both surgery and ECT.
Assuntos
Carcinoma de Células Escamosas , Doenças do Cão , Eletroquimioterapia , Neoplasias Cutâneas , Cães , Animais , Neoplasias Cutâneas/tratamento farmacológico , Neoplasias Cutâneas/veterinária , Neoplasias Cutâneas/patologia , Bleomicina/uso terapêutico , Eletroquimioterapia/veterinária , Doenças do Cão/tratamento farmacológico , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/veterinária , Carcinoma de Células Escamosas/patologiaRESUMO
Electrochemotherapy (ECT) is a tumor treatment that, through the application of electric pulses with suitable amplitude and waveforms, favors the systemic or local delivery of chemotherapy agents. This procedure significantly increases the permeability of cancer cells to anticancer drugs, making them more effective and allowing their use at lower doses with less morbidity for patients. Its use in veterinary oncology is consolidated and it is currently adopted as first-line treatment for different cancers with successful results. In human oncology, ECT use is mainly in the treatment of cutaneous tumors and for the palliation of cutaneous metastases of malignant tumors. A standard operating procedure has been formulated. Currently, several preclinical and phase I and II studies are under way involving various cancers in humans to better define the efficacy and tolerability of this therapy. This review summarizes the state of the art of ECT in veterinary and human oncology, describing the most significant results achieved to date.
Assuntos
Antineoplásicos , Eletroquimioterapia , Neoplasias Cutâneas , Humanos , Eletroquimioterapia/efeitos adversos , Eletroquimioterapia/métodos , Eletroquimioterapia/veterinária , Ciência Translacional Biomédica , Antineoplásicos/uso terapêutico , Neoplasias Cutâneas/etiologiaRESUMO
Background: Electrochemotherapy (ECT) promotes the increased uptake of antitumor agents through the administration of permeabilizing electric pulses, thus enhancing chemotherapy effectiveness. Aim: Our study aimed to describe the tolerability and efficacy of ECT alone or in association with surgery to manage solid neoplasms in equids. Methods: Medical records of equids with a diagnosis of malignant tumors treated with ECT alone or in combination with surgery were retrospectively evaluated. Each equid received local treatment within the tumors or the tumors' bed with cisplatin at the dose of 0.5 mg/cm2. Trains of permeabilizing biphasic electric pulses were then applied under spinal or general anesthesia. Results: Sixteen equids were enrolled in this study. There were nine melanoma cases, four fibrosarcoma, and three squamous cell carcinoma. Of those 16 equids, 7 received ECT for treatment of intraoperative local disease, while in 9 cases, ECT was the only treatment modality. The seven equids treated with the combination of ECT and surgery still have no evidence of disease at different times ranging from 9 to 60 months. The remaining nine had the following responses: two complete remissions, five partial responses, one stable disease, and one progressive disease. The treatment was well-tolerated, and local side effects were minimal. No systemic effects were documented. Conclusion: This retrospective study suggests that ECT may be beneficial for equids with solid neoplasms and could be a useful addition to the current therapeutic options considering its low cost, limited toxicity, and ease of administration.
Assuntos
Eletroquimioterapia , Neoplasias , Animais , Eletroquimioterapia/veterinária , Neoplasias/tratamento farmacológico , Neoplasias/veterinária , Estudos RetrospectivosRESUMO
Background: Electrochemotherapy (ECT) combines the administration of anticancer drugs with the delivery of electric pulses, thus increasing the drug uptake through the cell membranes, resulting in increased efficacy. Aim: The aim of our study was to describe the tolerability and efficacy of ECT alone or in association with other treatment modalities for the management of apocrine gland anal sac adenocarcinoma (AGASAC). Methods: Medical records of dogs with a diagnosis of AGASAC that were treated with ECT alone or in combination with surgery/chemotherapy were retrospectively evaluated. Each dog received 20 mg/m2 of bleomycin intravenously. Based on the clinician's decision, the primary tumor or tumor bed was also infiltrated with cisplatin at the dose of 0.5 mg/cm2. Trains of permeabilizing biphasic electric pulses were then applied under general anesthesia. Results: Ten dogs were enrolled in the study. Of those 10 dogs, only one received ECT for treatment of microscopic local disease, while in six cases ECT was the only treatment modality. In three dogs, ECT was followed by systemic medical treatment. Six dogs (60%) had a partial response (PR), three dogs (30%) had stable disease, and one dog treated for microscopic disease did not show any sign of local relapse for 305 days after treatment, being still alive and in complete remission at the time of writing this article. The median time to progression was 303 days and the median survival time was 365 days. The treatment was well tolerated and local side effects were minimal. No systemic effects were documented. Conclusion: This preliminary study suggests that ECT may be beneficial for dogs with AGASAC and could be a useful addition to the current therapeutic options in consideration of its low cost, limited toxicity, and ease of administration.
Assuntos
Adenocarcinoma/veterinária , Neoplasias das Glândulas Anais/terapia , Doenças do Cão/terapia , Eletroquimioterapia/veterinária , Neoplasias das Glândulas Sebáceas/veterinária , Adenocarcinoma/terapia , Sacos Anais/efeitos dos fármacos , Sacos Anais/patologia , Animais , Glândulas Apócrinas/efeitos dos fármacos , Glândulas Apócrinas/patologia , Cães , Eletroquimioterapia/estatística & dados numéricos , Feminino , Masculino , Estudos Retrospectivos , Neoplasias das Glândulas Sebáceas/terapiaRESUMO
Osteosarcoma is a bone cancer considered rare to humans, but common in dogs. Dogs and humans share genetic homology and environmental risk factors. Improving the treatment of osteosarcoma in dogs could also be relevant to improve procedures in humans. Traditional treatments of osteosarcoma involve surgery and chemotherapy. Such treatments are commonly aggressive and not possible for many patients. Electrochemotherapy emerges as a minimally invasive, effective, and safe treatment alternative. Electrochemotherapy combines applications of high-intensity electric fields during short periods with anti-cancer drugs to improve its medicine cytotoxicity. Analyzing the electric field distribution, as well as electric current density, are essential to electrochemotherapy success. This paper brings the first case of a canine osteosarcoma treatment performed with bleomycin and electrochemotherapy. We performed in silico studies with finite element method software to observe the electric field distribution. In silico experiments help to verify possibilities and limitations of treating bone destruction and macro or micro tumor infiltrations around the primary tumor mass. Results show that both needle or plate electrodes are feasible to remove the tumor even with invasion into the bone. Plate electrodes perform well in treating micro infiltrations when associated with conductive gel and direct contact between electrode and bone (without soft tissues). Needle electrodes are effective in treating tumor infiltration on external cortical bone. Multiple applications are needed to cover all cranium layers with sufficient electric field intensity. Electrochemotherapy protocol with needle or plate electrodes does not present sufficient electric current density capable of affecting brain tissue, even in cases of bone destruction.
Assuntos
Bleomicina/administração & dosagem , Procedimentos Cirúrgicos de Citorredução/métodos , Eletroquimioterapia/veterinária , Osteossarcoma/veterinária , Neoplasias Cranianas/veterinária , Animais , Quimioterapia Adjuvante/instrumentação , Quimioterapia Adjuvante/métodos , Quimioterapia Adjuvante/veterinária , Simulação por Computador , Cães , Eletroquimioterapia/instrumentação , Eletroquimioterapia/métodos , Eletrodos , Feminino , Modelos Biológicos , Osteossarcoma/terapia , Neoplasias Cranianas/terapiaRESUMO
Background: fFeline injection-site sarcomas (FISSs) are mesenchymal tumors that can occur in cats after injections of different medical agents and are easily prone to recurrence. Aim: The aims of this study were to report treatment outcomes for cats with feline injection-site sarcomas (FISSs) treated with both bleomycin and cisplatin, per adjuvant electrochemotherapy (ECT) protocol. Methods: The medical records of cats with a diagnosis of FISS that were treated with ECT using both bleomycin and cisplatin were retrospectively evaluated. A total of 27 cats were available for statistical evaluation of their response. The cats received intravenous 20 mg/m2 bleomycin, and the tumor bed and margins were infiltrated with cisplatin at the dose of 0.5 mg/cm2. Then, the trains of permeabilizing biphasic electric pulses lasting 50 + 50 µseconds each were delivered in bursts of 1,300 V/cm using caliper electrodes under sedation. A second session was performed 2 weeks later. Results: Side effects were limited to local inflammation in three cats. Three cats developed local tumor recurrence at days 180, 180, and 545 after surgery, two cats developed recurrence and metastases at 100 and 505 days after surgery, and two cats experienced distant metastases. A median time to recurrence could not be calculated as over 80% of the study population remained disease free or were censored due to death from other causes. Mean survival time was 985 days, and median cumulative survival for all cases was 1,000 days. Conclusion: When compared to historical controls, the results of this study demonstrate the superior rates of tumor-free survival and disease-free interval. This adjuvant therapy could be a useful addition to the current options for FISS in consideration of its efficacy, limited toxicity, and ease of administration.
Assuntos
Antineoplásicos/administração & dosagem , Bleomicina/administração & dosagem , Doenças do Gato/terapia , Quimioterapia Adjuvante/veterinária , Cisplatino/administração & dosagem , Eletroquimioterapia/veterinária , Reação no Local da Injeção/veterinária , Sarcoma/veterinária , Animais , Antibióticos Antineoplásicos/administração & dosagem , Gatos , Feminino , Reação no Local da Injeção/terapia , Masculino , Sarcoma/terapia , Neoplasias Cutâneas/terapia , Neoplasias Cutâneas/veterinária , Neoplasias de Tecidos Moles/terapia , Neoplasias de Tecidos Moles/veterinária , Resultado do TratamentoRESUMO
O carcinoma de células escamosas (CCE) é uma neoplasia maligna resultante da diferenciação de ceratinócitos, que acomete principalmente animais de pelagem clara e pouco pigmentados, decorrente da exposição à radiação ultravioleta. Apresentam evolução lenta e baixo caráter metastático, porém, em alguns mais avançados pode ocorrer acometimento metastático de órgãos adjacentes. Os tratamentos utilizados no CCE incluem cirurgia, radioterapia, quimioterapia, crioterapia e eletroquimioterapia (EQT). A eletroquimioterapia se mostra bastante eficaz no tratamento desse tumor, dentre outros e comumente não apresenta efeito colateral. O presente trabalho tem como objetivo relatar o caso de um felino atendido na Clínica Veterinária Bichos S.A. no município de Foz do Iguaçu, diagnosticado com Carcinoma de Células Escamosas e portador do vírus da imunodefiência felina. O tratamento adotado para a neoplasia foi a eletroquimioterapia, resultando em remissão parcial das lesões, após vinte dias da EQT. Com objetivo de investigar possível acometimento ósseo, foi realizada radiografia de face, onde a mesma apresentou área de lise óssea em arco zigomático e maxila esquerda, indicativo de infiltração neoplásica. A radiografia torácica apontou presença de área nodular sobrepondo lobo pulmonar caudal direito, indicativo de processo metastático. Em virtude do prognóstico reservado, os tutores optaram pela eutanásia do mesmo.(AU)
Squamous cell carcinoma (SCC) is a malignant neoplasm resulting from the differentiation of keratinocytes, which mainly affects light-colored and non-pigmented animals due to exposure to ultraviolet radiation. Although they present slow evolution and low metastatic character, in some more advanced cases, metastatic involvement of adjacent organs may occur. The treatments used in SCC include surgery, radiotherapy, chemotherapy, cryotherapy and electrochemotherapy (ECT). Electrochemotherapy is quite effective in the treatment of this type of tumor, among others, and it usually has no side effect. This work aims at reporting the case of a feline treated at the Veterinary Clinic Bichos S.A. in the city of Foz do Iguaçu diagnosed with Squamous Cell Carcinoma and carrying the feline immunodefense virus (FIV). Electrochemotherapy was the treatment of choice for the neoplasia, resulting in partial remission of the lesions after twenty days of treatment. In order to investigate possible bone involvement, an X-ray of the face was performed, where it presented area of bone lysis in the zygomatic arch and left maxilla, signs of neoplastic infiltration. The chest X-ray showed a nodular area overlapping the right caudal pulmonary lobe, an indication of metastatic process. Due to the reserved prognosis, the tutors chose euthanasia of the subject.(AU)
El carcinoma de células escamosas (CEC) es una neoplasia maligna resultante de la diferenciación de queratinocitos, que afecta principalmente a animales de pelaje claro y de poca pigmentación, resultado de la exposición a la radiación ultravioleta. Tienen una evolución lenta y un carácter metastásico bajo, sin embargo, en algunos más avanzados puede producirse afectación metastásica de órganos adyacentes. Los tratamientos utilizados en el CEC incluyen cirugía, radioterapia, quimioterapia, crioterapia y electroquimioterapia (EQT). La electroquimioterapia es muy eficaz en el tratamiento de ese tumor, entre otros y no suele tener efectos secundarios. Este trabajo tiene como objetivo reportar el caso de un felino atendido en la Clínica Veterinária Bichos S.A. de la ciudad de Foz do Iguaçu, diagnosticado con Carcinoma de Células Escamosas y con el virus de la inmunodeficiencia felina. El tratamiento adoptado para la neoplasia fue la electroquimioterapia, resultando en remisión parcial de las lesiones luego de veinte días de EQT. Con el fin de investigar la posible afectación ósea se realizó una radiografía de rostro, donde se presentó un área de lisis ósea en arco cigomático y maxilar izquierdo, indicativo de infiltración neoplásica. La radiografía de tórax mostró la presencia de un área nodular superpuesta al lóbulo pulmonar caudal derecho, lo que indicaba un proceso metastásico. Debido al pronóstico reservado, los tutores optaron por la eutanasia.(AU)
Assuntos
Animais , Gatos , Raios Ultravioleta , Carcinoma de Células Escamosas , Gatos/anormalidades , Eletroquimioterapia/veterinária , NotificaçãoRESUMO
Plasma cell tumors can occur as solitary collections referred as extramedullary plasmocytoma (EMP). The present report describes four cases of EMP treated with a local nonthermal ablative approach. Four dogs were diagnosed with extramedullary plasmocytomas (EMP) in different body regions (oral cavity, digits, and lip). Since surgical excision was declined by the owners (maxillectomy; amputation or lip reconstruction), a curative-intent approach was indicated as solely treatment- electrochemotherapy (ECT). All the patients received ECT under general anesthesia using bleomycin intravenously (15,000 UI/m²) or cisplatin intratumorally (1mg/cm³). All dogs developed transitory ulceration and swelling one-week after procedure that completely healed within 30 days post-ECT. Complete remission was achieved in all cases and lasted for 515 (oral case), 695 (one digit), 90 (another digit case) and 240 (lip) days. These results suggested that ECT promoted remission in EMP cases being a possibility for local control in dogs affected by this disease.
Assuntos
Antibióticos Antineoplásicos/uso terapêutico , Bleomicina/uso terapêutico , Cisplatino/uso terapêutico , Eletroquimioterapia/veterinária , Plasmocitoma/veterinária , Animais , Antibióticos Antineoplásicos/administração & dosagem , Bleomicina/administração & dosagem , Cisplatino/administração & dosagem , Doenças do Cão/tratamento farmacológico , Cães , Feminino , Masculino , Neoplasias Bucais/tratamento farmacológico , Plasmocitoma/tratamento farmacológico , Neoplasias Cutâneas/tratamento farmacológico , Resultado do TratamentoRESUMO
Background Oral malignant melanoma is the most common, but aggressive oral cancer in dogs with poor prognosis. Electrochemotherapy (ECT) has therapeutic potential in such tumors as effective local treatment. Therefore, the aim of this prospective clinical study was to evaluate treatment effectiveness of ECT in as first line treatment for canine oral malignant melanoma, and search for factors influencing treatment outcome. Methods Sixty-seven canines with primary oral malignant melanoma, non-candidates for first-line therapy, were enrolled. All dogs received ECT and follow-up exams for the span of two years. Results Based on RECIST criteria, the objective response rate was 100%, 89.5%, 57.7%, and 36.4%, in stage I, II, III and IV, respectively. Only patients in stage I, II and III with partial or complete response improved their quality of life. The median time to progression was 11, 7, 4 and 4 months, and median survival time after the treatment was 16.5, 9.0, 7.5 and 4.5 months, for patients in stage I, II, III and IV, respectively. Significantly better was local response in stage I and II disease (p = 0.0013), without the bone involvement (p = 0.043) Conclusions Electrochemotherapy is effective local treatment of oral canine malignant melanoma when no alternative treatment is available. Better response is expected in stage I and II patients with tumors without bone involvement.
Assuntos
Doenças do Cão/tratamento farmacológico , Eletroquimioterapia/veterinária , Melanoma/veterinária , Neoplasias Bucais/veterinária , Animais , Progressão da Doença , Intervalo Livre de Doença , Doenças do Cão/mortalidade , Doenças do Cão/patologia , Cães , Eletroquimioterapia/instrumentação , Eletroquimioterapia/métodos , Feminino , Seguimentos , Masculino , Melanoma/tratamento farmacológico , Melanoma/mortalidade , Melanoma/patologia , Neoplasias Bucais/tratamento farmacológico , Neoplasias Bucais/mortalidade , Neoplasias Bucais/patologia , Estadiamento de Neoplasias/veterinária , Estudos Prospectivos , Critérios de Avaliação de Resposta em Tumores Sólidos , Resultado do TratamentoRESUMO
The aim of this study was to evaluate the owners' perception of health-related quality of life (HRQoL) of dogs after treatment with electrochemotherapy (ECT) alone or combined with interleukin-12 gene electrotransfer (IL-12 GET) and/or surgery. The owners of 44 dogs with histologically different tumours were offered the ¼Cancer Treatment Form« at least one month after treatment. The owners assessed their dogs' quality of life (QoL) after treatment as good (mean 7.4) (from 1-very poor to 10-excellent) and the general health compared with the initial diagnosis of cancer as improving (mean 3.9) (from 1-worse to 5-better). The assessment of the current QoL was better within the group of dogs treated with non-invasive treatment (ECT and/or IL-12 GET only), compared with those that received invasive treatment, where, in addition to ECT and/or IL-12 GET, surgery was performed (p < .05). The owners of dogs that achieved an objective response (OR) to the treatment assessed the QoL as significantly better compared with those whose dogs did not respond to the treatment (p < .05). The majority of the owners (86.4%) would opt for the therapy again, regardless of the financial costs. In conclusion, the results of this study demonstrate that the majority of the owners of dogs assessed their dogs' QoL as good and felt that it improved after the treatment, especially in dogs, treated with non-invasive treatment and in those that responded to the treatment. This supports further use of ECT and IL-12 GET as suitable methods for the treatment of selected tumours in veterinary medicine.
Assuntos
Cães , Eletroquimioterapia/veterinária , Eletroporação/veterinária , Terapia Genética/veterinária , Interleucina-12/uso terapêutico , Qualidade de Vida , Animais , Eletroquimioterapia/estatística & dados numéricos , Eletroporação/estatística & dados numéricos , Feminino , Terapia Genética/estatística & dados numéricos , Masculino , Estudos ProspectivosRESUMO
The objective of the present study was to analyze the serum levels of the tumor marker Ca15.3 in healthy bitches and those with mammary neoplasms, correlating results with tumor type, clinical staging, time until presentation, and presence of ulceration and vascularization. For the study, 30 bitches with mammary tumors and 30 healthy bitches (control group) were selected. Histopathology was performed for identification of tumor type, and blood was collected for measurement of serum concentration of the marker via the chemiluminescence method using a commercial kit. A higher frequency of malignant neoplasms was observed (76.7%), with a higher quantity of carcinoma in mixed tumor (26.7%). Regarding serum concentration of the marker Ca15.3, there was no difference in serum values when comparing the means from bitches with neoplasia and healthy bitches, nor when comparing the other characteristics. The majority of results for serum concentration of Ca15.3, whether in bitches with neoplasia or in healthy bitches, was zero. It is concluded that the measurement of the marker Ca15.3 using the chemiluminescence method and commercial kits for humans did not offer significant results that would make this method or this marker a useful tool for patient monitoring and evaluation of the prognosis of bitches with mammary neoplasms.(AU)
Assuntos
Animais , Feminino , Cães , Biomarcadores Tumorais/sangue , Neoplasias Mamárias Animais , Mucina-1/administração & dosagem , Luminescência , Eletroquimioterapia/veterináriaRESUMO
Non-tonsillar squamous cell carcinoma (ntSCC) is a common and locally aggressive oral tumour in dogs. The treatments of choice are currently surgery and radiotherapy. Electrochemotherapy (ECT) is a local ablative anti-tumour technique using electric pulses to enhance the intracellular diffusion of cytotoxic drugs. The aim was to retrospectively evaluate the outcome of patients with oral ntSCC treated with ECT. Twelve dogs with ntSCC were retrospectively enrolled. ECT was combined with IV bleomycin (15 000 UI/m2 ) alone in 11 cases and post-surgery in 1. Parameters considered were: tumour site and size, electroporation parameters, response rate (complete remission [CR], partial remission [PR]), median survival time (MST), recurrence rate (RR), median disease-free interval (DFI) and treatment toxicity (6-point scale). Median tumour size was 1.65 cm (range 0.3-8.0 cm) and the response rate was 90.9% (10/11; 8 CR and 2 PR). Two dogs underwent a second ECT. MST for dogs dead with tumour (n = 2) was 110 days and for dogs dead without tumour (n = 3) was 831 days. Among five surviving dogs, one experienced tumour recurrence and four were in CR. Results from two dogs were analysed separately. Overall RR was 27.3%. DFI and MST for dogs with recurrence were 50 and 115 days, respectively. Treatment toxicity was very low. We noticed that all dogs with tumours smaller than 1-2 cm achieved CR without recurrence suggesting a favourable prognosis when using ECT. ECT for canine ntSCC could be considered a valid treatment option especially for smaller tumours, but a larger caseload would be needed to confirm this statement.
Assuntos
Carcinoma de Células Escamosas/veterinária , Doenças do Cão/tratamento farmacológico , Eletroquimioterapia/veterinária , Neoplasias Bucais/veterinária , Animais , Antibióticos Antineoplásicos/uso terapêutico , Bleomicina/uso terapêutico , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/patologia , Cães , Eletroquimioterapia/métodos , Feminino , Masculino , Neoplasias Bucais/tratamento farmacológico , Neoplasias Bucais/patologia , Recidiva Local de Neoplasia/tratamento farmacológico , Recidiva Local de Neoplasia/veterinária , Estudos Retrospectivos , Resultado do TratamentoRESUMO
Tumor microenvironment represents a key obstacle for the effectiveness of anticancer drugs. Electrochemotherapy involves the systemic or local delivery of lipophobic drugs such as bleomycin and cisplatin, with the application of permeabilizing electric pulses having appropriate amplitude and waveforms. This greatly enhances the uptake of these drugs by an estimated factor of 700-fold for bleomycin and 4 to 8 times for cisplatin. Because of its efficacy and limited morbidity, this therapeutic option is becoming more and more available in veterinary oncology either as an adjuvant to surgery or as first line of treatment with palliative or curative purposes.
Assuntos
Antineoplásicos/uso terapêutico , Doenças do Gato/tratamento farmacológico , Doenças do Cão/tratamento farmacológico , Eletroquimioterapia/veterinária , Neoplasias/veterinária , Animais , Gatos , Cães , Eletroquimioterapia/métodos , Oncologia , Neoplasias/tratamento farmacológico , Medicina VeterináriaRESUMO
Electrochemotherapy (ECT) couples the administration of anticancer drugs with the delivery of electric pulses that increase the drug uptake through the cell membranes, thus resulting in an improved efficacy. This study has evaluated the tolerability and efficacy of the combination of systemic bleomycin and local cisplatin as ECT agents for incompletely excised canine soft tissue sarcoma (STS). Thirty dogs with incompletely excised STSs were enrolled. The dogs received intravenous 20 mg/m2 bleomycin, and the tumor bed and margins were infiltrated with cisplatin at the dose of 0.5 mg/cm2. Then, trains of permeabilizing biphasic electric pulses were applied under sedation. More precisely, 5 min after the injection of the chemotherapy agents, sequences of eight biphasic pulses lasting 50 + 50 µsec each, were delivered in bursts of 1,300 V/cm using caliper electrodes. A second session was performed 2 wk later. The treatment was well tolerated and side effects were minimal. Twenty-six dogs had no evidence of recurrence at the time of manuscript writing; four had recurrence and one of the four recurring dogs died of lung metastases. Median estimated disease free was 857 d. Perivascular wall tumors response was compared to that of the other STSs, but the difference in outcome was not significant. ECT using combination of bleomycin and cisplatin appears to be effective in the treatment of incompletely resected STSs in dogs. This therapeutic approach could be a useful addition to the current options in consideration of its low cost, limited toxicity, and ease of administration.
Assuntos
Antineoplásicos/administração & dosagem , Bleomicina/administração & dosagem , Cisplatino/administração & dosagem , Doenças do Cão/terapia , Eletroquimioterapia/veterinária , Sarcoma/veterinária , Adjuvantes Farmacêuticos/administração & dosagem , Animais , Terapia Combinada/veterinária , Cães , Sarcoma/terapiaRESUMO
Fibropapillomatosis of sea turtles is traditionally treated with surgical debulking techniques that are often associated with prolonged healing and tumor recurrence. Electrochemotherapy was recently described for green turtles Chelonia mydas and can be an alternative to surgery and even general anesthesia. The objectives of this study were to replicate an electrochemotherapy protocol from a previous report and add plasma bleomycin analysis to the treatment. After bleomycin injection into similarly sized tumors of two green turtles and immediate electroporation at two time points, plasma bleomycin reached detectable concentrations that were considerably lower than those found in human studies. At 3 months posttherapy, no healing complications or recurrences were encountered and only scar tissue remained. This study adds further support that electrochemotherapy with bleomycin has the potential to be used as an effective alternative treatment for this complex disease.